Table of Contents
Table of Contents 3
List of Tables 7
List of Figures 8
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 9
Biogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 10
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 11
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 12
Biogen Inc, Medical Devices Deals, 2011 to YTD 2017 14
Biogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 15
Biogen Inc, Pharmaceuticals & Healthcare, Deal Details 20
Asset Purchase 20
Biogen Acquires CIRARA from Remedy Pharma 20
Biogen Idec Completes Acquisition Of Tysabri From Elan 21
Venture Financing 23
Solid Biosciences Raises USD50 Million in Series C Financing 23
Yumanity Therapeutics Raises USD45 Million in Series A Financing Round 25
Solid GT Raises USD42.5 Million in Series B Financing Round 26
True North Therapeutics Raises USD22 Million in Series A Venture Financing 27
Ataxion Raises US$17 Million In Series A Financing 29
iPierian Raises US$30 Million In Series A Venture Financing 30
Knopp Biosciences Raises US$15 Million In First Tranche Of Venture Financing 32
Probiodrug Secures US$19.5 Million In Series C Financing 33
Stromedix Secures US$2 Million In Venture Financing 35
Partnerships 36
Biogen Enters into Partnership with Genomics 36
Ewopharma Enters into Distribution Agreement with Biogen 37
Siemens Healthcare Enters into Co-Development Agreement with Biogen 38
Amyris Enters into Agreement with Biogen 39
Biogen Enters into Co-Development Agreement with University of Pennsylvania 40
AC Immune Enters into Partnership with Biogen 41
Rodin Therapeutics Enters into R&D Agreement with Biogen 42
Arsia Therapeutics Enters into Research Agreement with Biogen 43
BioMotiv Expands its Agreement with Biogen 44
Renovo Neural Partners with Biogen 45
Biogen Enters into Agreement with Parkinson’s Institute and Clinical Center 46
Biogen’s Partner Swedish Orphan Biovitrum To Exercise Its Option for Alprolix 47
Intec Pharma Enters into Research Agreement with Biogen MA 48
Biogen Idec, Fondazione Telethon and Ospedale San Raffaele Enter into Agreement to Develop Gene Therapies for Hemophilia 50
Biogen Idec Enters into Research Agreement with Columbia University Medical Center 51
Swedish Orphan Biovitrum Exercises Option Agreement with Biogen Idec for Elocta 52
Biogen Idec Expands Co-Development Agreement with Swedish Orphan Biovitrum 53
Array BioPharma Enters into Drug Discovery Agreement with Biogen Idec 54
Evotec Enters Into Agreement With Panion For Developing Chronic Pain Treatments 55
White Head Institute And Biogen Idec Enter Into Reasearch Agreement 56
Eisai Expands Co-Development Agreement with Biogen 57
Biogen Idec Enters Into Agreement With UCB To Commercialize Multiple Sclerosis And Hemophilia Therapies 59
Biogen Idec Enters Into Co-Marketing Agreement With Samsung Bioepis To Commercialize Anti-TNF Biosimilar Product Candidates 60
Amicus Therapeutics Enters Into Co-Development Agreement With Biogen Idec 61
Biogen Idec And Isis Pharma Enter Into R&D Agreement To Develop Treatments For Neurological Disorders 62
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drugs For Neurological Disorders 63
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drug For Myotonic Dystrophy 64
Samsung Forms Joint Venture With Biogen Idec 66
Biogen Idec Amends Co-Development Agreement With Swedish Orphan Biovitrum For rFVIIIFc And rFIXFc Hemophilia Programs 68
Biogen Idec Enters Into Co-Development Agreement With Isis Pharma 69
Adimab Enters Into Co-Development Agreement With Biogen Idec 71
Amunix Enters Into Co-Development Agreement With Biogen Idec 72
Licensing Agreements 73
Biogen Enters into Licensing Agreement with Bristol-Myers Squibb 73
Biogen Enters into Licensing Agreement with Forward Pharma 74
Biogen Exercises Option for Licensing Agreement with Amunix Operating for Factor IX, XTEN technology 76
Biogen Exercises Option for Licensing Agreement with Ionis Pharma 77
Biogen Enters into Licensing Agreement with RegenxBio 78
Biogen Enters into Licensing Agreement with Applied Genetic Technologies 79
Biogen Idec Enters into Licensing Agreement with Sangamo BioSciences for Hemoglobinopathies Therapeutics 81
Sunesis Pharma Enters Into Licensing Agreement With Biogen Idec 83
Biogen Idec Exercises Option For Licensing Agreement With Amunix Operating For XTENylated Factor VIII 84
Biogen Idec Enters Into Licensing Agreement With Adimab 85
Biogen Idec Enters Into Licensing Agreement With Myelin Repair Foundation 87
MAKScientific Enters Into Option For Licensing Agreement With Biogen Idec 88
Calchan Receives CNV2197944 and Certain Molecules from Convergence Pharma 89
ALS Therapy Development Institute Enters Into Option For Licensing Agreement With Biogen Idec And UCB Pharma 90
German Primate Center Enters Into Licensing Agreement With Biogen Idec 91
Equity Offering 92
Bioverativ Spin Off from Biogen 92
Biogen to Spin Off its Hemophilia Business 93
Rodin Therapeutics to Raise USD17.3 Million in Private Placement of Preferred Stock 94
Applied Genetic Tech Raises USD30 Million in Private Placement of Shares 95
Debt Offering 97
Biogen Raises USD1.5 Billion in Public Offering of 2.9% Notes Due 2020 97
Biogen Raises USD1.75 Billion in Public Offering of 5.2% Notes Due 2045 99
Biogen Raises USD1.75 Billion in Public Offering of 4.05% Notes Due 2025 101
Biogen Raises USD1 Billion in Public Offering of 3.625% Notes Due 2022 103
Asset Transactions 105
DRI Capital Acquires Royalty Rights To Benlysta From Biogen Idec 105
Eclipse Therapeutics Acquires Cancer Stem Cell Assets Of Biogen Idec 107
Acquisition 108
Biogen Idec Acquires Convergence Pharma for up to USD675 Million 108
Bristol-Myers Rumored To Acquire Biogen Idec 109
Biogen Idec Completes Acquisition Of Remaining Stake In Stromedix, Provider Of Therapies For Fibrosis 110
Takeda Completes Acquisition Of Intellikine For US$310 Million 112
Biogen Idec Acquires Remaining JV Stake In Biogen Dompe From Dompe 114
Biogen Idec To Acquire Companies Having Drugs In First Two Stages Of Testing 115
Biogen Inc – Key Competitors 116
Biogen Inc – Key Employees 117
Biogen Inc – Locations And Subsidiaries 119
Head Office 119
Other Locations & Subsidiaries 119
Joint Venture 123
Recent Developments 124
Strategy And Business Planning 124
Aug 09, 2016: Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company 124
May 03, 2016: Biogen Announces Intent to Spin off Its Hemophilia Business 125
Financial Announcements 127
Oct 24, 2017: Biogen Reports Quarterly Revenues of $3.1 Billion 127
Jul 25, 2017: Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance 129
Apr 25, 2017: Biogen Reports First Quarter 2017 Revenues of $2.8 Billion 132
Jan 26, 2017: Biogen Reports 2016 Revenues of $11.4 Billion 134
Oct 26, 2016: Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion 136
Jul 21, 2016: Biogen Reports Second Quarter 2016 Revenues of $2.9 Billion 138
Apr 21, 2016: Biogen Reports First Quarter 2016 Revenues of $2.7 Billion 141
Jan 27, 2016: Biogen 2015 Revenues Increase 11% to $10.8 Billion 143
Corporate Communications 145
Nov 21, 2017: Biogen Appoints Jeff Capello as Executive Vice President and Chief Financial Officer 145
Sep 25, 2017: Biogen Appoints Camille Lee as SVP, Alzheimer’s Disease Therapeutic Area 146
Sep 12, 2017: Biogen Appoints Sanjay Jariwala as SVP, Worldwide Medical 147
Jun 20, 2017: Biogen Appoints Ginger Gregory Executive Vice President, Chief Human Resources Officer 148
Jun 14, 2017: Jean-Paul Kress Appointed EVP and President, International and Head of Global Therapeutic Operations 149
Jun 13, 2017: Biogen Announces Management Change 150
Mar 16, 2017: Biogen Appoints Anirvan Ghosh Senior Vice President, Research and Early Development 151
Feb 01, 2017: Biogen Completes Separation of Global Hemophilia Business, Bioverativ 152
Jan 12, 2017: Biogen Spin-off Bioverativ Commences When-Issued Trading of Common Stock 153
Dec 19, 2016: Biogen Names Michel Vounatsos Chief Executive Officer 154
Nov 15, 2016: Biogen announces management changes 155
Mar 30, 2016: Biogen Appoints Michel Vounatsos Executive Vice President, Chief Commercial Officer 156
Legal and Regulatory 157
Sep 05, 2017: Forward Pharma Files Opening Brief in the Appeal of the U.S. Patent Interference to the Federal Circuit 157
May 01, 2017: Forward Pharma Further Aligns Cost Structure with Focus Following Settlement and License Agreement 158
Feb 09, 2017: Forward Pharma Received US$ 1.25bn pursuant to Settlement and License Agreement with Biogen 159
Government and Public Interest 160
Feb 10, 2016: Biogen and Target ALS Foundation Announce $20 Million Corporate Funding Challenge 160
Product News 161
09/21/2016: TSRI Study Illuminates How Mystery MS Drug Works 161
09/14/2016: Tecfidera (Dimethyl Fumarate) Real-World Studies Affirm Sustained Efficacy And Demonstrate 9-Year Safety Profile 163
09/08/2016: Biogen To present Data on TECFIDERA (dimethyl fumarate) at the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis 165
08/18/2016: Remedy Pharmaceuticals Edema and Neuro-inflammation Advisory Board Provides Guidance on Opportunities in CNS Conditions 167
04/12/2016: Biogen to Present Data on TECFIDERA at 2016 AAN Annual Meeting 168
04/12/2016: Biogen to Present Data on TYSABRI (Natalizumab) at 2016 AAN Annual Meeting 169
04/06/2016: Remedy Pharmaceuticals Issues First Quarter 2016 Report 170
03/28/2017: Biogen to Present Data on BIIB054 at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases 171
03/18/2016: New research gathers more evidence for innovative stroke treatment 172
02/03/2016: BIIB076 (anti-tau mAb) moving into pre-IND toxicology studies 173
Product Approvals 174
Jan 16, 2017: Remedy Pharmaceuticals CIRARA Granted Orphan Drug Designation For Treatment of Severe Cerebral Edema Caused By Acute Ischemic Stroke 174
Jun 08, 2016: Remedy Pharmaceuticals Receives FDA Fast Track Designation for CIRARA 175
Jun 01, 2016: Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Accepted into European Medicines Agency’s PRIME Program 176
May 31, 2016: Biogen Receives Positive CHMP Opinion for TYSABRI (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Response to Prior MS Therapy 177
May 31, 2016: Roche’s subcutaneous formulation of MabThera receives approval in Europe for people with chronic lymphocytic leukaemia 178
May 26, 2016: Elan Pharma International Withdraw an application for a change to the marketing authorisation for Tysabri (natalizumab) 179
Feb 26, 2016: EMA confirms recommendations to minimise risk of brain infection PML with Tysabri 180
Feb 16, 2016: Remedy Pharmaceuticals Announces FDA Orphan Drug Designation in Two CNS Indications 183
Feb 12, 2016: Updated recommendations to minimise the risk of the rare brain infection PML with Tysabri 184
Jan 15, 2016: Pharmacovigilance Risk Assessment Committee (PRAC) provides update on ongoing referral on Tysabri 186
Clinical Trials 187
Feb 19, 2017: BIIB076 Moves into Phase 1 for Alzheimer Disease 187
Dec 08, 2016: Biogen Presents Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimer’s Disease Meeting 188
Sep 01, 2016: Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Granted FDA Fast Track Designation 190
Aug 31, 2016: Nature Publishes Results from Pre-Clinical Research and Phase 1b Study of Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab 191
Aug 23, 2016: Phase III trial planned for drug to reduce brain swelling from stroke 192
Jun 07, 2016: Remedy Pharmaceuticals Announces Contest to Name its Subarachnoid Hemorrhage Clinical Trial 193
Apr 18, 2016: TECFIDERA Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness 194
Apr 11, 2016: Remedy Pharmaceuticals Announces Two Oral Presentations on Results of CNS-Related Edema Trial At Annual American Academy of Neurology Meeting 197
Mar 04, 2016: Remedy Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting With FDA on a Novel Drug Treatment for CNS-Related Edema 198
Feb 22, 2016: Remedy Pharmaceuticals Announces Additional Results From Phase 2 CNS-Related Edema Study of CIRARA Presented at International Stroke Conference 199
Feb 08, 2016: Remedy Pharmaceuticals Announces Acceptance of Two Oral Presentations on Phase 2 Results of CIRARA for CNS-Related Edema at ISC 2016 200
Jan 05, 2016: CNS-Related Edema Company Remedy Pharmaceuticals Strengthens Leadership Team in Preparation for Phase 3 Trial 202
Other Significant Developments 203
Dec 22, 2016: Biogen Announces Effectiveness of Bioverativ Form 10 Registration Statement 203
Nov 30, 2016: Sangamo’s Genome Editing Program for Hemoglobinopathies to Transfer to Biogen’s Spin-Off Bioverativ 204
Feb 08, 2016: Biogen Joins Pioneering Target Validation Collaboration 205
Appendix 206
Methodology 206
About GlobalData 206
Contact Us 206
Disclaimer 206
Biogen Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 9
Biogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 10
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 11
Biogen Inc, Deals By Therapy Area, 2011 to YTD 2017 12
Biogen Inc, Medical Devices Deals, 2011 to YTD 2017 14
Biogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 15
Biogen Acquires CIRARA from Remedy Pharma 20
Biogen Idec Completes Acquisition Of Tysabri From Elan 21
Solid Biosciences Raises USD50 Million in Series C Financing 23
Yumanity Therapeutics Raises USD45 Million in Series A Financing Round 25
Solid GT Raises USD42.5 Million in Series B Financing Round 26
True North Therapeutics Raises USD22 Million in Series A Venture Financing 27
Ataxion Raises US$17 Million In Series A Financing 29
iPierian Raises US$30 Million In Series A Venture Financing 30
Knopp Biosciences Raises US$15 Million In First Tranche Of Venture Financing 32
Probiodrug Secures US$19.5 Million In Series C Financing 33
Stromedix Secures US$2 Million In Venture Financing 35
Biogen Enters into Partnership with Genomics 36
Ewopharma Enters into Distribution Agreement with Biogen 37
Siemens Healthcare Enters into Co-Development Agreement with Biogen 38
Amyris Enters into Agreement with Biogen 39
Biogen Enters into Co-Development Agreement with University of Pennsylvania 40
AC Immune Enters into Partnership with Biogen 41
Rodin Therapeutics Enters into R&D Agreement with Biogen 42
Arsia Therapeutics Enters into Research Agreement with Biogen 43
BioMotiv Expands its Agreement with Biogen 44
Renovo Neural Partners with Biogen 45
Biogen Enters into Agreement with Parkinson's Institute and Clinical Center 46
Biogen’s Partner Swedish Orphan Biovitrum To Exercise Its Option for Alprolix 47
Intec Pharma Enters into Research Agreement with Biogen MA 48
Biogen Idec, Fondazione Telethon and Ospedale San Raffaele Enter into Agreement to Develop Gene Therapies for Hemophilia 50
Biogen Idec Enters into Research Agreement with Columbia University Medical Center 51
Swedish Orphan Biovitrum Exercises Option Agreement with Biogen Idec for Elocta 52
Biogen Idec Expands Co-Development Agreement with Swedish Orphan Biovitrum 53
Array BioPharma Enters into Drug Discovery Agreement with Biogen Idec 54
Evotec Enters Into Agreement With Panion For Developing Chronic Pain Treatments 55
White Head Institute And Biogen Idec Enter Into Reasearch Agreement 56
Eisai Expands Co-Development Agreement with Biogen 57
Biogen Idec Enters Into Agreement With UCB To Commercialize Multiple Sclerosis And Hemophilia Therapies 59
Biogen Idec Enters Into Co-Marketing Agreement With Samsung Bioepis To Commercialize Anti-TNF Biosimilar Product Candidates 60
Amicus Therapeutics Enters Into Co-Development Agreement With Biogen Idec 61
Biogen Idec And Isis Pharma Enter Into R&D Agreement To Develop Treatments For Neurological Disorders 62
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drugs For Neurological Disorders 63
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drug For Myotonic Dystrophy 64
Samsung Forms Joint Venture With Biogen Idec 66
Biogen Idec Amends Co-Development Agreement With Swedish Orphan Biovitrum For rFVIIIFc And rFIXFc Hemophilia Programs 68
Biogen Idec Enters Into Co-Development Agreement With Isis Pharma 69
Adimab Enters Into Co-Development Agreement With Biogen Idec 71
Amunix Enters Into Co-Development Agreement With Biogen Idec 72
Biogen Enters into Licensing Agreement with Bristol-Myers Squibb 73
Biogen Enters into Licensing Agreement with Forward Pharma 74
Biogen Exercises Option for Licensing Agreement with Amunix Operating for Factor IX, XTEN technology 76
Biogen Exercises Option for Licensing Agreement with Ionis Pharma 77
Biogen Enters into Licensing Agreement with RegenxBio 78
Biogen Enters into Licensing Agreement with Applied Genetic Technologies 79
Biogen Idec Enters into Licensing Agreement with Sangamo BioSciences for Hemoglobinopathies Therapeutics 81
Sunesis Pharma Enters Into Licensing Agreement With Biogen Idec 83
Biogen Idec Exercises Option For Licensing Agreement With Amunix Operating For XTENylated Factor VIII 84
Biogen Idec Enters Into Licensing Agreement With Adimab 85
Biogen Idec Enters Into Licensing Agreement With Myelin Repair Foundation 87
MAKScientific Enters Into Option For Licensing Agreement With Biogen Idec 88
Calchan Receives CNV2197944 and Certain Molecules from Convergence Pharma 89
ALS Therapy Development Institute Enters Into Option For Licensing Agreement With Biogen Idec And UCB Pharma 90
German Primate Center Enters Into Licensing Agreement With Biogen Idec 91
Bioverativ Spin Off from Biogen 92
Biogen to Spin Off its Hemophilia Business 93
Rodin Therapeutics to Raise USD17.3 Million in Private Placement of Preferred Stock 94
Applied Genetic Tech Raises USD30 Million in Private Placement of Shares 95
Biogen Raises USD1.5 Billion in Public Offering of 2.9% Notes Due 2020 97
Biogen Raises USD1.75 Billion in Public Offering of 5.2% Notes Due 2045 99
Biogen Raises USD1.75 Billion in Public Offering of 4.05% Notes Due 2025 101
Biogen Raises USD1 Billion in Public Offering of 3.625% Notes Due 2022 103
DRI Capital Acquires Royalty Rights To Benlysta From Biogen Idec 105
Eclipse Therapeutics Acquires Cancer Stem Cell Assets Of Biogen Idec 107
Biogen Idec Acquires Convergence Pharma for up to USD675 Million 108
Bristol-Myers Rumored To Acquire Biogen Idec 109
Biogen Idec Completes Acquisition Of Remaining Stake In Stromedix, Provider Of Therapies For Fibrosis 110
Takeda Completes Acquisition Of Intellikine For US$310 Million 112
Biogen Idec Acquires Remaining JV Stake In Biogen Dompe From Dompe 114
Biogen Idec To Acquire Companies Having Drugs In First Two Stages Of Testing 115
Biogen Inc, Key Competitors 116
Biogen Inc, Key Employees 117
Biogen Inc, Other Locations 119
Biogen Inc, Subsidiaries 119
Biogen Inc, Joint Venture 123
